Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Exagen (XGN) Shares Outstanding (2018 - 2026)

Exagen filings provide 9 years of Shares Outstanding readings, the most recent being $24.1 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding rose 34.2% to $24.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $24.1 million, a 34.2% increase, with the full-year FY2025 number at $22.9 million, up 29.88% from a year prior.
  • Shares Outstanding hit $24.1 million in Q1 2026 for Exagen, up from $22.9 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $24.1 million in Q1 2026 to a low of $16.2 million in Q1 2022.
  • Median Shares Outstanding over the past 5 years was $17.3 million (2024), compared with a mean of $18.4 million.
  • Biggest five-year swings in Shares Outstanding: decreased 4.1% in 2022 and later soared 34.2% in 2026.
  • Exagen's Shares Outstanding stood at $16.5 million in 2022, then increased by 3.0% to $17.0 million in 2023, then increased by 3.49% to $17.6 million in 2024, then rose by 29.88% to $22.9 million in 2025, then grew by 5.13% to $24.1 million in 2026.
  • The last three reported values for Shares Outstanding were $24.1 million (Q1 2026), $22.9 million (Q4 2025), and $22.5 million (Q3 2025) per Business Quant data.